Trial · NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
NCT04973605, Phase 1, Phase 2, Recruiting, BeOne Medicines
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma. Trials, record NCT04973605. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04973605
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT number
- NCT04973605
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 246 participants, estimated
- Lead sponsor
- BeOne Medicines
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide
- First posted
- 2021-07-22
- Last updated
- 2026-10-26
- Other registries' IDs
- eudract:2021-003614-39
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs) | Up to 28 days | DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol. |
| Primary | Part 1 And 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events Leading to Discontinuation and Adverse Events of Special Interest (AESIs). | Up to 30 days after last dose of study drug | |
| Primary | Part 2: Overall response rate (ORR) as Assessed by Investigator | Approximately 4 years | Defined as the percentage of participants who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria |
| Primary | Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator | Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years] | Defined as the percentage of participants with a documented VGPR or better (including sCR, CR, and VGPR) |
| Primary | Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator | Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]) | defined as the percentage of participants with a documented CR or sCR |
| Secondary | Part 1: Area under the plasma concentration-time curve time 0 to the last measurable concentration (AUClast) After a Single Dose of Sonrotoclax | Cycle 1 (each cycle is up to 28 days) | |
| Secondary | Part 1: Maximum observed plasma concentration (Cmax) After a Single Dose of Sonrotoclax | Cycle 1 (each cycle is up to 28 days) | |
| Secondary | Part 1: Time to reach Cmax (tmax) After a Single Dose of Sonrotoclax | Cycle 1 (each cycle is up to 28 days) | |
| Secondary | Part 1: At Steady-state: AUC last, ss | Cycle 2 (each cycle is up to 28 days) | |
| Secondary | Part 1: At Steady-state: Cmax, ss | Cycle 2 (each cycle is up to 28 days) |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04973605
GET https://conductscience.org/api/trials/v1/NCT04973605/registered